UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	OMB APPROVAL							
	OMB Number:	3235-0362						
	Estimated average bu	rden						
cs	hours per response	1.0						

subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 3 Holdings Reported

Form 4 Transactions

Reported

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Wallar Gina M			2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) (Middle)			3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)				/Year)	X Officer (give title below) Other (specify below) President, Pharma Services			
9490 NEOGENOMICS WAY			12/31/2021								
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Reporting (check applicable line)			
FORT MYERS, FL 33912								_X_ Form Filed by One Reporting Person Form Filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price		of (D)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	Ownership Form:	Beneficial Ownership	
Common Stock		12/31/2021		L(1)	363	A	\$ 35.28	21,662	D		

owned directly or indirectly.

Reminder: Report on a separate line for each class of securities beneficially Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)		3A. Deemed Execution Date, if	4. Transaction Code	5.	rative rities ired rosed	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Securities	8. Price of Derivative Security (Instr. 5)	of	Ownership Form of	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 9.22					(2)	04/19/2023	Common Stock	6,667.00		6,667	D	
Stock Option (Right to Buy)	\$ 13.87					(3)	12/12/2023	Common Stock	8,334.00		8,334	D	
Stock Option (Right to Buy)	\$ 20.83					(4)	05/01/2026	Common Stock	7,153.00		7,153	D	
Stock Option (Right to Buy)	\$ 27.34					(5)	05/01/2027	Common Stock	7,879.00		7,879	D	
Stock Option (Right to Buy)	\$ 48.99					(6)	05/01/2028	Common Stock	8,595.00		8,595	D	
Stock Option (Right to Buy)	\$ 43.95					(7)	07/05/2028	Common Stock	10,126.00		10,126	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	Director 0 Officer Officer		Other				
Wallar Gina M 9490 NEOGENOMICS WAY FORT MYERS, FL 33912			President, Pharma Services					

Signatures

/s/ Gina M. Wallar	02/08/2022
***Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These shares were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the year ended December 31, 2021. The shares were acquired in transactions exempt from Section 16b-3.
- (2) On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.
- (3) On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.
- (4) On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- (5) On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- (6) On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- (7) On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.